← All problems

Problem

Predicting antibody developability from sequence

Predict, from the heavy/light-chain sequence alone, the biophysical properties that decide whether an antibody binder can become a manufacturable, stable, injectable drug: hydrophobicity (HIC retention), polyreactivity, self-association (AC-SINS), thermostability (Tm) and expression titer. Commercially, developability failures are a main reason good binders die between discovery and the clinic, so an accurate in-silico filter saves months of wet-lab characterisation per program and is the pitch of BigHat, LabGenius and Generate. Current public state of the art (Ginkgo 2025 AbDev competition, held-out GDPa1 antibodies) is Spearman rho ~0.71 for hydrophobicity but only ~0.39 for thermostability, with polyreactivity, self-association and titer in between or lower. A practical 'solved' bar would be held-out Spearman >= 0.8 on every one of the five assays on new antibody families, i.e. accurate enough to replace the assay for ranking candidates; no public model is near that on Tm, titer or self-association.

Funding

$223M

Raised by the 3 companies working on it, 2 undisclosed.

Prize money for solving it$0
Open competition pools$0

Why it is still open

In Ginkgo Datapoints' 2025 AbDev competition (252 registered teams, 115 submissions) the best held-out Spearman correlations were 0.708 for hydrophobicity and only 0.392 for thermostability; per-property winners differed, and no single model predicted all five properties well.

Source: datapoints.ginkgo.bio

Who is working on it

BigHat Biosciences$223M ML-guided antibody design loop with in-house cell-free expression and high-throughput assays that co-optimises binding and developability properties; partnered with Lilly, J&J, Lonza; lead ADC BHB810 in Phase 1. InvestorsDFJ Growth, Premji Invest, Andreessen Horowitz, 8VC, Amgen Ventures, Alexandria Venture Investments, Catalio Capital Management, LG Technology Ventures
LabGenius Therapeuticsundisclosed EVA automated ML discovery engine that co-optimises multispecific antibodies across multiple properties (selectivity, killing, developability) for solid tumours; partnered with Sanofi (Dec 2025) and LG Chem (Jun 2026). InvestorsM Ventures, Octopus Ventures, Atomico, Kindred Capital, Lux Capital, Obvious Ventures
Generate:Biomedicinesundisclosed Generative protein/antibody design platform (Chroma and successors) that designs antibodies with developability built in; lead antibody GB-0895 in Phase 3; developability is one of several objectives. InvestorsFlagship Pioneering, Amgen, Novartis

Also active

Ginkgo Datapoints (Ginkgo Bioworks) Sells high-throughput developability assay data (PROPHET-Ab platform, GDPa1 dataset) and ran the 2025 AbDev prediction competition; supplies the ground truth rather than the predictor.

Funding for these is not counted: the problem is a small part of what they do, or they contribute data and tools.

Prizes

PrizeStatusPays forAmount
Ginkgo Datapoints 2025 Antibody Developability CompetitionAwardedRanking$60k

What counts as solved

The acceptance condition, stated in Lean 4. Measurements a computer cannot produce on its own are named inputs, supplied by whoever attests them.

import Mathlib

/-!
# Predicting antibody developability from sequence

Modelled on the Ginkgo Datapoints 2025 AbDev competition (GDPa1 panel): predict
developability assay values from heavy/light-chain sequence alone, scored by Spearman
rank correlation on a hidden test set, per property.

Concrete in Lean: the candidate object (a predictor: sequence pair → ℝ per property),
the Spearman correlation over a finite held-out set (Pearson of average ranks, ties
averaged), and "beats the pinned baseline by margin δ on every property".

Opaque oracle (`HeldOut`): the hidden antibodies and their measured assay values
(e.g. HIC retention, Tm2 / thermostability, expression titer, polyreactivity, AC-SINS
self-association), plus which baseline is pinned. Attester: the data owner (Ginkgo
Datapoints or the board's CRO), who must also attest the set was not released before
the submission was frozen (hash committed first).

Units: each property in its own assay units; Spearman is dimensionless in [-1, 1].
Sign convention: the oracle orients each property so larger = more developable, or the
board scores |ρ|; this file uses signed ρ.
-/

namespace OpenSpur.Problems.AntibodyDevelopability

/-- Heavy / light chain amino-acid sequences. -/
structure Antibody where
  heavy : String
  light : String

/-- Candidate submission: one score per property index. -/
abbrev Predictor (nProps : ℕ) := Fin nProps → Antibody → ℝ

noncomputable section

/-- Average (1-based) rank of entry i, ties receive the mean of their positions. -/
def avgRank {n : ℕ} (x : Fin n → ℝ) (i : Fin n) : ℝ :=
  ((Finset.univ.filter fun j => x j < x i).card : ℝ)
    + (((Finset.univ.filter fun j => x j = x i).card : ℝ) + 1) / 2

def mean {n : ℕ} (x : Fin n → ℝ) : ℝ := (∑ i, x i) / n

def pearson {n : ℕ} (x y : Fin n → ℝ) : ℝ :=
  (∑ i, (x i - mean x) * (y i - mean y)) /
    Real.sqrt ((∑ i, (x i - mean x) ^ 2) * (∑ i, (y i - mean y) ^ 2))

def spearman {n : ℕ} (x y : Fin n → ℝ) : ℝ := pearson (avgRank x) (avgRank y)

/-- Hidden test set for one property (oracle). -/
structure HeldOut where
  n : ℕ
  antibody : Fin n → Antibody
  measured : Fin n → ℝ
  baselineRho : ℝ          -- Spearman of the pinned baseline on this set

def rho (h : HeldOut) (f : Antibody → ℝ) : ℝ :=
  spearman (fun i => f (h.antibody i)) h.measured

structure Thresholds where
  minN : ℕ        -- e.g. 50 antibodies per property
  margin : ℝ      -- δ, e.g. 0.05
  minRho : ℝ      -- absolute floor, e.g. 0.3

/-- SOLVED: on every property, ρ ≥ max(floor, baseline + δ) with a large enough set. -/
def Solved {p : ℕ} (T : Thresholds) (sets : Fin p → HeldOut) (f : Predictor p) : Prop :=
  0 < p ∧ ∀ k, T.minN ≤ (sets k).n ∧
    (sets k).baselineRho + T.margin ≤ rho (sets k) (f k) ∧ T.minRho ≤ rho (sets k) (f k)

def rung (T : Thresholds) (k : ℕ) : Thresholds :=
  { T with margin := T.margin + (k : ℝ) / 20 }

end

theorem rung_mono {p : ℕ} (T : Thresholds) (sets : Fin p → HeldOut) (f : Predictor p)
    {j k : ℕ} (hjk : j ≤ k) (h : Solved (rung T k) sets f) : Solved (rung T j) sets f := by
  have hc : (j : ℝ) ≤ k := by exact_mod_cast hjk
  refine ⟨h.1, fun i => ?_⟩
  obtain ⟨a, b, c⟩ := h.2 i
  refine ⟨a, ?_, c⟩
  simp only [rung] at b ⊢
  linarith

end OpenSpur.Problems.AntibodyDevelopability

Public resources

Join

Tell us what you want settled.

Two questions. We read every one.

I am a

What are you looking to solve?

Where should we reply?

Received

That is with us.

We read every message and reply to the ones we can help.